

Patient Support for Induction and Maintenance Module 6

Today's Presenters

Claire Nolan, PharmD

Program Manager for MI-CCSI's involvement in the Michigan Overdose Data to Action (MODA) program, content expert, faculty member, and participant in practice transformation initiatives. Dr. Nolan has experience in community, specialty, and ambulatory pharmacy.

Robin Schreur, BS, RN, CCM

Trainer for MI-CCSI with care management experience in the primary care, behavioral health, and payer settings. She has trained hundreds of clinicians on the care management process and motivational interviewing. Her love of and partnership with patients, families and clinicians is rooted in early work as a psychiatric nurse and the deep conviction that care management is a privilege and calling.



Disclosure

MI-CCSI, or the presenter, does not have any financial interest, relationships, or other potential conflicts, with respect to the material which will be covered in this presentation.

Patient-Centered Treatment for Substance Use Disorder in Primary Care



	Clinical		Operational
Module	Title	Module	Title
1	Navigating Buprenorphine Prescribing for the Primary Care Physician	2	Substance Use Disorder and Patient Identification
3	Buprenorphine Medical Management: Monitoring the Patient	4	OBAT Eligibility, Intake and Assessment
5	Challenging Clinical Scenarios in MOUD: Early Refills and Lost or Stolen Medication	6	Patient Support for Induction and Maintenance
7	Complex Cases in Buprenorphine Treatment, Part 1	8	Operationalizing Team Meetings, Systematic Case Review, & Documentation
9	Complex Cases in Buprenorphine Treatment, Part 2	10	Team Roles and Responsibilities
11	Pain and Addiction	12	Supporting the Patient Beyond Buprenorphine

Action Period Assignment From Module 4

- Identify the tool your team will use to determine patient eligibility for office-based treatment of addiction.
- Define the process your team will follow for intake into the program.





OBJECTIVES

At the conclusion of this presentation, the participant will be able to:

- Describe the buprenorphine induction process (clinic and community), including management of withdrawal symptoms.
- Recognize best practices for buprenorphine maintenance and stabilization.
- Explain general principles of buprenorphine treatment discontinuation.



10/8/21

AGENDA

1	Review
2	Buprenorphine Induction
3	Buprenorphine Maintenance and Stabilization
4	Discontinuation of Buprenorphine Treatment
5	Practice Interviews



REVIEW

Previous Modules

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center.

Improve, Enhance, Restore

Office-Based Addiction Treatment (OBAT)

- Patient-focused
- Evidence-based
- Primary care / community model
- Offer of medication and psychosocial therapies as a component of a comprehensive care plan
- Select patients identified via screening may be candidates for OBAT

https://www.bmcobat.org/resources/index.php?filename=22 2021 Clinical Guidelines 06.22.21.FINAL.pdf





8






SUD Screening Screen for OBAT Participation **OBAT** Intake (NCM) Initial Provider Assessment Induction **Stabilization and Maintenance Discontinuation of Treatment**









Buprenorphine Induction

11

Buprenorphine / Naloxone

Pharmacology Overview

- Partial mu agonist
 - \downarrow cravings
 - \downarrow withdrawal
 - X acute effects of other opioids
- Co-formulation with naloxone (opioid antagonist) decreases intravenous (IV) abuse

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 13, 2021.

DOSAGE FORM	BRAND NAME	ACTIVE INGREDIENT(s)
Film, buccal	Belbuca [®]	Buprenorphine
Film, buccal	Generic only	Bup / Naloxone
Film, sublingual	Suboxone®	Bup / Naloxone
Implant, SubQ	Probuphine Implant Kit®	Buprenorphine
Patch, transdermal	Butrans®	Buprenorphine
Solution, injection	Buprenex®	Buprenorphine
Solution, SubQ PFS	Sublocade®	Buprenorphine
Tablet, sublingual	Generic only	Buprenorphine
Tablet, sublingual	Zubsolv®	Bup / Naloxone




Buprenorphine / Naloxone Administration

• Buccal

- Moisten inside of cheek with tongue or water prior to administration
- Press and hold film in place for 5 seconds with finger
- Keep film in place until fully dissolved (up to 30 min)
- Do not chew, swallow, touch, or move film
- Avoid eating or drinking
- Avoid application to any area with open sores or lesions
- Sublingual
 - Place under the tongue until dissolved (up to 10 min)
 - Do not chew or swallow





Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Aquestive Therapeutics. (2021). Suboxone: Medication Guide. Warren, NJ: Author.

Buprenorphine Induction General Principles

- Initiate therapy ASAP
- Review induction plan with the patient prior to prescribing
- Communicate directly with pharmacy to ensure product availability is aligned with induction plan

Prior to Induction

- Treatment agreement and consent reviewed and signed
- Patient engagement confirmed (e.g., ability to attend frequent appointments)
- Offer connection to counseling
- Obtain toxicology
- Complete pregnancy testing, when appropriate

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf



Transitioning to Treatment Discontinuation of Drug Use



- Before buprenorphine induction, the patient must first discontinue drug use
 - Often referred to as "full agonist discontinuation"
 - Recommended timing of drug discontinuation varies
- Induction begins when the patient is in mild-to-moderate withdrawal
 - Assess using standardized tool (e.g., Clinical Opiate Withdrawal Scale [COWS])
 - Exception: buprenorphine micro-dosing
- Goal is to avoid *precipitated* withdrawal

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Transitioning to Treatment Discontinuation of Drug Use

- Timeline for discontinuation of drug use dependent on:
 - Drug's half-life
 - Patient's individualized treatment plan
 - Patient-specific risk for complications

urrent Opiola Ose	Discontinuation time Frame
ort-acting opioids, ther than fentanyl	8-12 hours prior to scheduled initiation
Fentanyl	At least 16-24 hours prior to scheduled initiation
ong-acting opioids	At least 12-24 hours prior to scheduled initiation
Methadone	When possible, discontinue at a dose of 30 mg or less at least 36-96 hours prior to scheduled buprenorphine initiation

Current Onioid Use

Sh

ot

LC

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf



Discontinuation Time Frame

Clinical Opiate Withdrawal Scale (COWS) Assessing for Opiate Withdrawal

- 11-item scale
- Summed score can identify current state / severity of opiate withdrawal
- Can be tracked over timed



https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf



17

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center.


Clinical Opiate Withdrawal (COWS) Assessing for Opiate Withdrawal

Score indicated level of withdrawal

- 5-12 = mild withdrawal*
- 13-24 = moderate*
- 25-34 = moderately severe
- > 35 = severe


* goal prior to buprenorphine induction

https://www.bmcobat.org/resources/index.php?filename=22 2021 Clinical Guidelines 06.22.21.FINAL.pdf





In-Office Induction Day 1 Workflow – Patient Arrives in Withdrawal




Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22 2021 Clinical Guidelines 06.22.21.FINAL.pdf

ter for Clinical Systems Improveme

In-Office Induction



Day 1 Workflow – Patient Arrives Not in Withdrawal




Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

In-Office Induction



Day 1 Workflow – Patient Arrives Not in Withdrawal (continued)



Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf



Before you begin you want to feel sick from your withdrawal symptoms You should feel at least four of these symptoms ... It should be at least ... - Body aches - 12 hours since you used heroin/or pain pills - Restlessness - Goose bumps - Tremors/twitching 16 hours since you last used fentanyl - Frequent yawning Stomach cramps, nausea, 48-72 hours since you used methadone - Enlarged pupils - Chills or sweating vomiting or diarrhea - If you used more than one drug, use the longest - Anxious or irritable - Runny nose/eyes wait time before starting buprenorphine. Once you are ready, follow these instructions to start the medication **DAY 2: DAY 1:** 8 to 16 mg 8-24 mg of buprenorphine of buprenorphine Step 1. Step 2. Step 3. Take 8 to 16 mg dose Still Stop Still feel sick? Wait 6 Take the Wait 45 uncomfortable? Take next dose hours first dose minutes Take last dose 8 to 16 mg 6 45 Stop 4 to 8 mg 4 to 8 mg 4 to 8 mg hours minutes If you took 16mg or more on day 1 take a total of 16mg - If you took less than 16mg and Put the tablet or strip under your tongue You may need up to 24mg to - Stop after this dose felt well take that dose. manage withdrawal on day 1. - Do not exceed 24mg on Day 1 Keep it there until fully dissolved If you have questions or troubles Most will do well with 16mg (about 15 min.) follow up with the clinical team. Do NOT eat. drink or smoke 15 min before Do NOT swallow the medicine Contact the clinic or emergency number given to you if your symptoms get worse.

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance, Boston Medical Center, https://www.bmcobat.org/resources/index.php?filename=22 2021 Clinical Guidelines 06.22.21.FINAL.pdf

A Guide for **Patients Beginning Buprenorphine Treatment**

10/8/21




Buprenorphine Stabilization and Maintenance

Buprenorphine Stabilization



Days 2-7 and Beyond



Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. <u>https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf</u>

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

Buprenorphine Stabilization Follow-Up

- Patient-specific
 - Support needs
- Weekly visits typically continue for 4-6 weeks
- Stable:
 - Steady dose
 - Minimal to no withdrawal symptoms or cravings
 - Progress made towards treatment goals

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.





Buprenorphine Stabilization Follow-Up



- Assess/review/evaluate
 - Treatment plan
 - Adherence
 - Drug use
 - Symptoms of opioid withdrawal and/or cravings
 - Support patient self-management (e.g., relapse prevention planning)
 - Additional support needs

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22 2021 Clinical Guidelines 06.22.21.FINAL.pdf

Withdrawal Symptoms General Principles



- Optimize buprenorphine dose
- Proactively communication with patient what to expect
- Avoid pre-treatment beyond buprenorphine
- Symptom management in line with management related to other causes
- Patients unable to tolerate withdrawal symptoms may require referral to a specialist

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Withdrawal Symptoms



Medication Management

- Alpha-2 adrenergic agonist
 - Clonidine, tizanidine, lofexidine
 - Most effective for autonomic symptoms
 - Least effective for muscle aches, restlessness, insomnia, and cravings
- Symptoms-specific therapy

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

Withdrawal Symptoms Symptoms-Specific Therapy




Anxiety	• Hydroxyzine, clonidine, lofexidine
Insomnia	• Sedating antidepressants (e.g., trazodone), antihistamines (e.g., hydroxyzine, diphenhydramine)
Musculoskeletal Pain	NSAIDs, acetaminophen, heat packs, topical analgesics
Gastrointestinal Issues	• Antiemetic (e.g., ondansetron), antispasmodics (e.g., dicyclomine), anti-diarrheal (e.g., bismuth subsalicylate), oral hydration
Restless legs	• Muscle relaxants (e.g., tizanidine), dopamine promoter (e.g., ropinerole)
Rhinorrhea	 Antihistamines (e.g., hydroxyzine, diphenhydramine)

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22 2021 Clinical Guidelines 06.22.21.FINAL.pdf

Buprenorphine Maintenance Clinic Visits

- Consider patient preferences and support needs in follow-up planning
 - Visits with provider should occur at least every 3-4 months
- Medication refills coincide with visits
- Provide support outside of clinic visits (e.g., telephonic outreach)
- Relapse prevention planning
- OBAT Training and Technical Assistance Manual
 - Nursing Follow-Up Note (pages 110-114)

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf






Buprenorphine Maintenance Supporting Long-Term Recovery

- Monitoring and evaluation focused on patient-centered care
- Treatment plan revisions should be expected
 - Visit frequency
 - Medication (e.g., dose, quantity)
 - Care coordination
 - Level of care

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf






Recurrent Use

Relapse Prevention Plan

- Periods of recurrent use are expected
- Preparing the patient is a critical component of person-centered care
- Document a relapse prevention plan in collaboration with the patient
- The more specific the better





Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

University of Washington Psychiatry & Behavioral Sciences. (2014). Relapse Prevention Plan. AIMS Center. https://aims.uw.edu/sites/default/files/RelapsePreventionPlan.pdf

Relapse Prevention Plan

Points for Consideration

Triggers

- What are some of my everyday stressors?
- Was there a specific time of the day I was more prone to substance use?
- Did specific people participate in my use?
- What caused me to relapse in the past?

Warning Signs

- Who in my life can help me identify warning signs?
- Review a list of warning signs and identify those that have been relevant in the past

Coping Strategies

- What coping strategies have worked for me in the past?
- How can I remind myself to use these strategies?
- Brainstorm outlets for pain/frustration (e.g., exercise, journaling)
- Create a list of supportive resources or people to call

University of Washington Psychiatry & Behavioral Sciences. (2014). Relapse Prevention Plan. AIMS Center. https://aims.uw.edu/sites/default/files/RelapsePreventionPlan.pdf

How to Create a Successful Relapse Prevention Plan. (2021, April 22). Retrieved from https://www.therecoveryvillage.com/treatment-program/aftercare/related/relapse-prevention-plan/





Discontinuation of Buprenorphine Treatment

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

- **Buprenorphine Discontinuation** A Note on Treatment Duration
 - Substance use disorder is a complex chronic condition
 - A pre-defined treatment duration is not recommended
 - Longer treatment duration associated with improved outcomes
 - \downarrow mortality
 - Patients may choose to discontinue medication for addiction treatment



35

Buprenorphine Discontinuation General Principles



- Team-based support continues
 - Ongoing recovery support
 - Dose adjustments / management of withdrawal symptoms
 - Regular check-ins via telephone
- Individualized buprenorphine taper
 - Gradual (e.g., months) > rapid (e.g., days)

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. <u>https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf</u>

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

Buprenorphine Discontinuation Individualized Buprenorphine Taper



• Gradual (e.g., months) > rapid (e.g., days)

- Reduce dose by 2 mg every 1-2 weeks
- Adjust continuously based on patient response
 - Withdrawal symptoms
 - Protracted abstinence syndrome

Massachusetts Nurse Care Model of Office Based Addiction Treatment: Clinical Guidelines. (2021). Office Based Addiction Treatment Training and Technical Assistance. Boston Medical Center. https://www.bmcobat.org/resources/index.php?filename=22_2021_Clinical_Guidelines_06.22.21.FINAL.pdf

Lexicomp Online, Access Lexicomp Online, Hudson, Ohio: UpToDate, Inc.; 2021; July 22, 2021.

HOMEWORK Action Period

- Identify the tools your team will use to support the buprenorphine induction process.
- Define the process your team will follow for relapse prevention planning, in collaboration with the patient.







Thank You

Please email <u>Claire.Nolan@miccsi.org</u> with any questions.



How does your practice support patients during the induction and maintenance stage for buprenorphine treatment?

10/8/21